Advertisement

Inflammation Research

, Volume 49, Issue 12, pp 692–699 | Cite as

The in vitro and in vivo pharmacology of antisense oligonucleotides targeted to murine Stat6

  • H. Danahay
  • S. Hill
  • F. Natt
  • C.E. Owen

Abstract.

Objective and Design: This study was designed to establish whether phosphorothioate (PS) antisense oligonucleotides (AS-ODN) targeted to Stat6 were active in vivo in a mouse model of active sensitisation.¶Materials: Female Balb/c mice (6-8) per group were used for in vivo study.¶Treatment: Mice were treated with active PS AS-ODNs determined in initial in vitro studies. Compounds were dosed daily (3-30mg/kg i.v.) over the course of sensitisation to ovalbumin.¶Methods: Stat6 mRNA and protein levels were determined in the spleen after treatment (quantitative northern and western analysis respectively), in addition to serum IgE (ELISA). ANOVA was used to determine any significant differences between groups.¶Results: Both of the AS-ODNs tested in vivo, down regulated Stat6 mRNA and protein levels in the spleen by 40-50% although there was no effect on serum IgE. These treatments also induced splenomegaly in vivo and caused s plenocyte proliferation in vitro.¶Conclusions: The AS-ODNs used can down regulate Stat6 mRNA and protein although not sufficiently to influence IgE-levels. These effects are likely to be complicated in vivo by the immune-stimulation evident as splenomegaly.

Key words: Signal transduction – mRNA – In vivo animal models – Gene regulation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser Verlag, 2000

Authors and Affiliations

  • H. Danahay
    • 1
  • S. Hill
    • 1
  • F. Natt
    • 2
  • C.E. Owen
    • 1
  1. 1.Novartis Horsham Research Centre, Wimblehurst Road Horsham, West Sussex, RH12 5AB, UK, e-mail: henry.danahay@pharma.novartis.comUK
  2. 2.Core Technology Group, Novartis Pharma AG, Lichtstrasse 35, 4056 Basle, SwitzerlandCH

Personalised recommendations